Metoprolol is processed almost entirely by the liver, so the organ is central to how the drug works in your body. Despite that heavy hepatic involvement, actual liver damage from metoprolol is rare. Published reports of metoprolol-induced liver injury are limited mostly to mild bumps in liver enzymes, with only a single documented case of severe liver failure in the medical literature. That said, the relationship between metoprolol and your liver runs deeper than just the risk of toxicity: pre-existing liver disease, your genetic makeup, and other medications you take can all change how much metoprolol ends up in your bloodstream, which in turn affects both its benefits and its side effects.
How the Liver Processes Metoprolol
When you swallow a metoprolol tablet, the drug passes through your stomach and into the small intestine, where it gets absorbed into the bloodstream. Before it can circulate through the rest of your body, though, it first travels to the liver. There, enzymes break down a large portion of the dose before it ever reaches your heart. This “first-pass” effect is why only about half of an oral dose makes it into general circulation in a healthy person.
The main liver enzyme responsible for breaking down metoprolol is called CYP2D6. For years, researchers assumed CYP2D6 handled nearly all of the work, but studies using human liver tissue have shown that other enzymes chip in too. CYP3A4, CYP2B6, and CYP2C9 together contribute a meaningful share of metoprolol’s breakdown, accounting for roughly a fifth of one metabolic pathway and smaller but real contributions to others.1Frontiers in Pharmacology. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug This matters because it means anything that speeds up or slows down these enzymes, whether it is another drug, a genetic quirk, or liver disease, can change how much metoprolol actually reaches your heart.
Can Metoprolol Cause Liver Damage?
Drug-induced liver injury is a well-known concern with many medications, and beta-blockers as a class are not completely exempt. But metoprolol sits at the very low end of that risk spectrum. The published case literature describes liver injury from metoprolol as “very rare,” with most reports limited to a mild, isolated rise in transaminases, the enzymes that leak into the blood when liver cells are stressed.2PubMed Central. Metoprolol-induced Severe Liver Injury and Successful Management with Therapeutic Plasma Exchange Those bumps typically show up on routine blood work and resolve when the drug is stopped or the dose is lowered.
Only one case in the literature has described a severe outcome: a patient with coronary heart disease developed jaundice and hepatic encephalopathy, a dangerous condition where toxins build up because the liver can no longer clear them properly. That case was treated successfully with therapeutic plasma exchange, a procedure that filters harmful substances from the blood.2PubMed Central. Metoprolol-induced Severe Liver Injury and Successful Management with Therapeutic Plasma Exchange The rarity of this event is itself telling: metoprolol is one of the most widely prescribed beta-blockers in the world, taken by millions of people, and documented cases of serious liver injury remain in the single digits.
There is a broader question about whether liver toxicity might be shared across all beta-blockers rather than being specific to one drug. A case report involving a patient who developed liver injury on one beta-blocker and then again after switching to a different one raised exactly this possibility, suggesting hepatotoxicity could be a class effect.3PubMed Central. β-Blocker-Induced Liver Injury: A Class Effect With Incidental Rechallenge If that is true, switching from metoprolol to another beta-blocker after a liver reaction might not solve the problem. This remains an area with very little data, so clinicians approach it on a case-by-case basis.
What Happens If You Already Have Liver Disease
For someone whose liver is already compromised, the math around metoprolol changes significantly. Remember that first-pass effect, where a healthy liver clears about half the drug before it reaches the rest of the body? In patients with cirrhosis, the liver’s filtering capacity is reduced. A study comparing cirrhosis patients with healthy volunteers found that the average amount of metoprolol reaching the bloodstream jumped from about 50% in healthy people to roughly 84% in those with cirrhosis.4PubMed. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis That means the same pill delivers substantially more active drug to the heart and blood vessels.
The drug also lingers longer. The same study found that metoprolol’s half-life, the time it takes for blood levels to drop by half, stretched from about four hours in healthy subjects to over seven hours in cirrhosis patients.4PubMed. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis Higher peak levels plus slower elimination add up to a much stronger effect from the same dose. This is why doctors often start with lower doses and adjust cautiously in people with known liver problems. Symptoms of excessive metoprolol, such as dangerously slow heart rate, fatigue, dizziness, or drops in blood pressure, are more likely when the liver cannot clear the drug efficiently.
Beta-Blockers as Treatment in Liver Cirrhosis
Ironically, while liver disease complicates metoprolol dosing, beta-blockers are actually a cornerstone of managing one of cirrhosis’s most dangerous complications: portal hypertension. When the liver becomes scarred and stiff, blood backs up in the portal vein, raising pressure and creating fragile, dilated veins called varices in the esophagus and stomach. If those varices rupture, the bleeding can be life-threatening. Non-selective beta-blockers like propranolol and nadolol (not metoprolol, which is selective) have long been used to lower portal pressure and prevent variceal bleeding.
The complication arises in patients with very advanced cirrhosis and refractory ascites, where fluid accumulates in the abdomen and no longer responds to standard diuretic treatment. In these cases, evidence has raised concerns that beta-blocker therapy could actually cause harm, potentially lowering blood pressure and cardiac output to dangerous levels in a body that is already struggling to maintain circulation.5PubMed Central. The changing role of beta-blocker therapy in patients with cirrhosis Clinicians managing cirrhosis patients on any beta-blocker, metoprolol included, need to balance the drug’s cardiovascular benefits against the liver’s declining ability to both tolerate and metabolize it.
How Your Genes Change the Equation
Not everyone’s liver handles metoprolol the same way, even among people with perfectly healthy livers. The CYP2D6 enzyme that does most of the metabolic work comes in many genetic variants. Depending on which versions you inherited, you might be an “ultra-rapid metabolizer” who burns through the drug quickly, an “extensive metabolizer” who processes it at the expected rate, or a “poor metabolizer” whose enzyme barely works at all.
The clinical consequences are real. A guideline from the Clinical Pharmacogenetics Implementation Consortium found high-level evidence that poor metabolizers experience significantly greater drug exposure and lower heart rates from metoprolol compared to everyone else.6PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy In practical terms, a poor metabolizer on a standard dose of metoprolol might get the same blood levels that a normal metabolizer would get on a much higher dose. That extra exposure translates into more pronounced effects on heart rate and blood pressure, and it means the liver is bathed in higher concentrations of the drug for longer periods.
On the other end of the spectrum, ultra-rapid metabolizers may clear metoprolol so fast that normal doses barely work. Their doctors might need to prescribe higher-than-typical doses or switch to a different beta-blocker altogether. Pharmacogenomic testing, a simple cheek swab or blood test, can identify your CYP2D6 status before you start the drug, though it is not yet standard practice everywhere.
Drug Interactions That Overload Liver Processing
Because metoprolol depends so heavily on CYP2D6, any other medication that blocks that enzyme can mimic the effect of being a genetic poor metabolizer. Two of the most commonly prescribed culprits are the antidepressants paroxetine and fluoxetine, both of which are strong CYP2D6 inhibitors. A systematic review found that paroxetine can increase metoprolol blood levels by three to five times, while also causing noticeable drops in blood pressure and heart rate.7PubMed Central. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine For a patient who felt fine on metoprolol alone, adding one of these antidepressants could tip them into symptomatic bradycardia or hypotension seemingly out of nowhere.
The interaction is not limited to antidepressants. A case report described acute liver injury in a patient taking both metoprolol and dacomitinib, an anti-cancer drug that also strongly inhibits CYP2D6. The likely mechanism was straightforward: dacomitinib blocked the enzyme, metoprolol accumulated, and the elevated levels damaged liver cells.8PubMed. Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib The authors stressed that liver function should be closely monitored when metoprolol is combined with strong CYP2D6 inhibitors. Other drugs in this category include quinidine, bupropion, and terbinafine, among others. If you are prescribed a new medication and you are already on metoprolol, it is worth asking your pharmacist whether there is a CYP2D6 interaction.
On the flip side, drugs that rev up liver enzymes, known as inducers, can slash metoprolol levels and make it less effective. Rifampicin, an antibiotic used mainly for tuberculosis, is a potent inducer of CYP3A4, CYP2B6, and CYP2C9, the secondary enzymes that help metabolize metoprolol.1Frontiers in Pharmacology. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug A patient starting rifampicin while on metoprolol might notice their blood pressure or heart rate creeping back up as their liver chews through the beta-blocker faster than expected.
Signs to Watch For
Routine liver monitoring is not standard for everyone taking metoprolol, because the risk of liver injury is so low. But there are situations where paying attention to your liver makes sense:
- New fatigue or nausea: These overlap with common metoprolol side effects, but if they appear suddenly after weeks or months of tolerating the drug well, mention them to your doctor.
- Yellowing skin or eyes: Jaundice is the most visible sign of significant liver trouble and always warrants urgent evaluation.
- Dark urine or pale stools: These suggest that bilirubin, a waste product normally processed by the liver, is not being handled properly.
- Right upper abdominal pain: Discomfort beneath the right ribs can signal liver inflammation.
These symptoms are uncommon with metoprolol, but they deserve prompt attention if they show up, especially if you are also taking a CYP2D6 inhibitor, have underlying liver disease, or carry a poor-metabolizer genotype.
Metoprolol Pharmacokinetics During Pregnancy
Pregnancy reshapes how the body handles many drugs, and metoprolol is a clear example. During pregnancy, increased blood flow to the liver and changes in enzyme activity speed up drug metabolism. A pharmacokinetic study found that metoprolol clearance roughly doubled in mid-pregnancy and nearly tripled by late pregnancy compared to postpartum values.9PubMed Central. Pharmacokinetics of metoprolol during pregnancy and lactation The effect was especially pronounced in extensive metabolizers. Because the drug is cleared so much faster, pregnant women may need significantly higher doses or more frequent dosing to maintain adequate blood-pressure or heart-rate control.
This is essentially the opposite of what happens in liver disease: instead of the drug accumulating because the liver cannot keep up, it vanishes faster because the liver is working overtime. The clinical advice from researchers is that if metoprolol is not controlling symptoms adequately during pregnancy, doctors should be prepared to escalate the dose aggressively or consider a different medication rather than assuming the drug simply is not working.9PubMed Central. Pharmacokinetics of metoprolol during pregnancy and lactation After delivery, clearance drops back toward normal, which means a dose that was appropriate during the third trimester could become excessive postpartum. Close follow-up in the weeks after giving birth is important to avoid side effects from suddenly having too much drug in the system.
Why the Liver Connection Matters More Than the Toxicity Risk
Most conversations about “does this drug affect the liver” revolve around whether the drug can poison the organ. With metoprolol, the more important and more common issue runs in the other direction: the state of your liver affects the drug. A liver slowed by cirrhosis, blocked by a competing medication, or genetically short on CYP2D6 activity can turn a standard dose into an overdose. A liver supercharged by pregnancy or an enzyme-inducing drug can render a standard dose almost useless.
If you are taking metoprolol and something changes, whether it is a new prescription, a diagnosis involving your liver, a planned pregnancy, or even genetic test results you did not have before, it is worth revisiting your metoprolol dose with your prescriber. The drug itself is unlikely to harm your liver, but your liver has an outsized say in whether metoprolol helps you or causes problems.